Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01527916 · ClinicalTrials.gov registry record · Phase 2

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 2
Development phase
438
Enrollment target

NCT01527916: Completed Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).

NCT01527916 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 438 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (229% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01527916, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 2
Development phase
438 participants
Enrollment target

Study Summary

This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

Interventions

  • DRUG placebo
  • DRUG ABT-126
  • DRUG donepezil

Trial Details

FieldValue
Enrollment Target 438 participants
Start Date 2012-02
Est. Completion 2013-11
Phase Phase 2
AbbVie (prior sponsor, Abbott)

88 total trials

What the finished NCT01527916 record still lists

NCT01527916 is an interventional study that assigns participants to a tested intervention. The registered 438 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (229% higher).

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT01527916 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01527916 about?

NCT01527916 is a clinical study titled "Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease". This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

What is the current status of trial NCT01527916?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 438 participants. The study started on 2012-02. Estimated completion is 2013-11.

What interventions are being tested in trial NCT01527916?

The interventions under investigation include: placebo (DRUG), ABT-126 (DRUG), donepezil (DRUG).

Who is sponsoring clinical trial NCT01527916?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01527916's enrollment target sits among peer trials

438 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05711446 · 438 participants · NA

    Double Voiding and Post-transplant UTI

  • NCT05421663 · 439 participants · Phase 1

    A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

  • NCT06235151 · 439 participants · Phase 3

    Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

  • NCT05114538 · 440 participants · NA

    Improving the Part C Early Intervention Service Delivery System for Children with ASD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01527916, the US trial registry maintained by the National Library of Medicine. NCT01527916 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.